BioAdaptives

BioAdaptives Financial Debt Ratio

The Financial Debt Ratio of BioAdaptives (BDPT) as of Oct 26, 2026 is 170.18 %. In the previous year, Financial Debt Ratio was 131.01 % — a change of 29.89% (higher).

Financial Debt Ratio

170.18 %

YoY

29.89%

Last updated:

Financial Debt Ratio of BioAdaptives is 2025 170.18 % . Financial Debt Ratio of BioAdaptives was 2024 131.01 % . It decreases by 29.89% higher compared to the previous year.

The BioAdaptives Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2018
79.79 USD
Jan 1, 2019
1,528.56 USD
Jan 1, 2020
2,562.62 USD
Jan 1, 2021
293.99 USD
Jan 1, 2022
1,050.65 USD
Jan 1, 2023
316.52 USD
Jan 1, 2024
131.01 USD
Jan 1, 2025
170.18 USD
The BioAdaptives Financial Debt Ratio history
YEARFinancial Debt RatioYoY
170.18 %+29.89%
131.01 %-58.61%
316.52 %-69.87%
1,050.65 %+257.37%
293.99 %-88.53%
2,562.62 %+67.65%
1,528.56 %+1,815.84%
79.79 %—
0.00—
0.00—
0.00-100.00%
48.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

Financial Debt Ratio of BioAdaptives is 170.18 % in 2025.

Financial Debt Ratio of BioAdaptives changed from 131.01 % to 170.18 %, representing a 29.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's BioAdaptives with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioAdaptives

All Key Metrics — BioAdaptives